sellWeak cluster of 510b5-1 plan
Alexandra Balcom sold $2.5M of NUVL
Chief Financial Officer at Nuvalent, Inc.. 25,130 shares at an average of $98.15, traded Mar 24, 2026, filed Mar 26, 2026.
Warning score
32Value
$2.5M
25,130 shares
Holdings after
85,533
-23% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +25Trade size$2.5M at market
- +5Share of holdings soldSold 23% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001862147-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | MOption exercise Class A Common Stock10b5-1 | +11,430 | $1.08 | $12k | 110,663 | Mar 26, 2026 |
| Mar 24, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -2,599 | $95.03 | $247k | 108,064 | Mar 26, 2026 |
| Mar 24, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -7,671 | $95.88 | $735k | 100,393 | Mar 26, 2026 |
| Mar 24, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,160 | $96.50 | $112k | 99,233 | Mar 26, 2026 |
| Mar 25, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -13,700 | $100.16 | $1.4M | 85,533 | Mar 26, 2026 |
| Mar 24, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,430 | $0.00 | $0 | 150,226 | Mar 26, 2026 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.